| abstract |
A duocarmycin antibody-drug conjugate (ADC) is provided that exhibits improved in vivo anti-tumor activity. Human solid tumors and hematopoietic tumors expressing HER2, in particular breast cancer, stomach cancer, bladder cancer, ovarian cancer, lung cancer, prostate cancer, pancreatic cancer, colon cancer, head and neck squamous cell carcinoma or osteosarcoma, and It relates to a duocarmycin-containing antibody-drug conjugate (ADC) for use in the treatment of acute lymphoblastic leukemia. In particular, it relates to a duocarmycin-containing ADC for use in the treatment of human solid tumors with HER2 IHC2 + or 1+ and HER2 FISH negative tissue conditions. Advantageously, a duocarmycin-containing ADC for use in the treatment of triple negative breast cancer (TNBC). Combinations of said compounds with therapeutic antibodies and / or chemotherapeutic agents. [Selection figure] None |